Roth Capital Downgrades Titan Pharmaceuticals (TTNP) to Neutral Citing Probuphine Ramp Delay
Tweet Send to a Friend
Roth Capital downgraded Titan Pharmaceuticals (NASDAQ: TTNP) from Buy to Neutral with a price target of $2.00 (from $6.00).Analyst Scott ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
